Types of Change in Coronary Stenosis Severity and Their Relative Importance in Overall Progression and Regression of Coronary Disease: Observations from the FATS Triala
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical trials using niacin, alone or in combination with other lipid medications, have shown benefits in decreasing cardiovascular event rates and atherosclerosis.
“Clinical trials using niacin, alone or in combination with other lipid medications, have shown benefits in decreasing cardiovascular event rates and atherosclerosis (173-176).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [175]
Cites
Untitled work
Brown, G. (1990) · Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med
UnresolvedUntitled work
G., B. B. (1977) · Quantitative coronary arteriography: estimation of dimensions, hemodynamic resistance, and atheroma mass of coronary artery lesions using the arteriogram and digital computation. Circulation
UnresolvedUntitled work
G., B. B. (1986) · Quantitative computer techniques for analyzing coronary arteriograms. Prog. Cardiovasc. Dis
UnresolvedQuantitative Arteriography: Update
Brown, B. (1993)
UnresolvedUntitled work
E., A. H. (1971) · Progression of proximal coronary artery lesions to total occlusion after aorta-coronary saphenous vein bypass grafting. J. Thorac. Cardiovasc. Surg
UnresolvedUntitled work
P., L. P. (1986) · Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation
UnresolvedUntitled work
X‐Q., Z. (1991) · Increased potential for regression of post-PTCA restenosis using intensive lipid-altering therapy: comparison with matched non-PTCA lesions. JACC
UnresolvedUntitled work
A., D. M. (1980) · Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N. Engl. J. Med
UnresolvedUntitled work
J., D. M. (1976) · Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi. Br. Heart. J
UnresolvedUntitled work
H., B. D. (1987) · Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. (Published erratum appears in JAMA 1988 May 13;
UnresolvedUntitled work
H., B. D. (1992) · Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect. Circulation
UnresolvedUntitled work
F., B. J. (1984) · Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation
UnresolvedUntitled work
L., G. K. (1992) · Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. Am. J. Cardiol
UnresolvedUntitled work
Waters, D. (1993) · Prognostic significance of progression of coronary atherosclerosis. Circulation
UnresolvedUntitled work
Buchwald, H. (1992) · Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. JAMA
Unresolved
Flagged first, then by citations
15 of the 15 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Takemoto, M., & Liao, J. K. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1101.098486 · Cited by 1,268 · see citing works
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094 · see citing works
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · see citing works
Kontush, A., & Chapman, M. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.1 · Cited by 752 · see citing works
Callister, T. Q., Raggi, P., Cooil, B., Lippolis, N. J., & Russo, D. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812313392703 · Cited by 681 · see citing works
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 527 · see citing works
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds
Birjmohun, R. S., Hutten, B. A., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.031 · Cited by 429 · see citing works
“In line, nicotinic acid derivatives, mediating HDL increase through a variety of mechanisms (7,8), have been associated with a reduction of CV events in one large monotherapy trial and two small combination secondary prevention trials (9,10).”
Steinmetz, E. F., Buckley, C., Shames, M. L., Ennis, T. L., VanVickle-Chavez, S. J., Mao, D., Goeddel, L. A., Hawkins, C. J., & Thompson, R. W. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000150258.36236.e0 · Cited by 169 · see citing works
MRI and Characterization of Atherosclerotic Plaque
Choudhury, R. P., Fuster, V., Badimón, J. J., Fisher, E. A. A., & Fayad, Z. A. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000019735.54479.2f · Cited by 142 · see citing works
Maccubbin, D., Bays, H. E., OLSSON, A. G., Elinoff, V., Elis, A., Mitchel, Y., Sirah, W., Betteridge, A., Reyes, R., Yu, Q., et al. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01938.x · Cited by 115 · see citing works
Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia
Miida, T., Hirayama, S., & Nakamura, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.253 · Cited by 97 · see citing works
Maccubbin, D., Koren, M. J., Davidson, M., Gavish, D., Pasternak, R. C., Macdonell, G., Mallick, M., Sisk, C. M., Paolini, J. F., & Mitchel, Y. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.02.047 · Cited by 71 · see citing works
Effects of statins on the vasculature
Sowers, J. R. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03269-1 · Cited by 67 · see citing works
Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art
Crouse, J. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600012-jlr200 · Cited by 66 · see citing works
Choudhury, R. P., Aguinaldo, J. G. S., Rong, J. X., Kulak, J. L., Kulak, A., Reis, E. D., Fallon, J. T., Fuster, V., Fisher, E. A. A., & Fayad, Z. A. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00730-4 · Cited by 57 · see citing works
Lai, E., Waters, M. G., Tata, J. R., Radziszewski, W., Perevozskaya, I. T., Zheng, W., Wenning, L. A., Connolly, D. T., Semple, G., Johnson‐Levonas, A. O., et al. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.08.445 · Cited by 56 · see citing works
Tracking atherosclerosis regression: a clinical tool in preventive cardiology
Taylor, A. J., Shaw, L. J., Fayad, Z. A., O’Leary, D., Brown, B. G., Nissen, S. E., Rader, D. J., & Raggi, P. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.12.024 · Cited by 48 · see citing works
Self-citationShah, S., Češka, R., Extremera, B. G., Paolini, J. F., Giezek, H., Vandormael, K., Mao, A., Sisk, C. M., & Maccubbin, D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02370.x · Cited by 37 · see citing works
Safety of extended-release niacin/laropiprant in patients with dyslipidemia
McKenney, J. M., Bays, H. E., Koren, M. J., Ballantyne, C. M., Paolini, J. F., Mitchel, Y., Betteridge, A., Kuznetsova, O., Sapre, A., Sisk, C. M., et al. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.02.002 · Cited by 33 · see citing works
Tracking Coronary Calcification by Using Dual-Section Spiral CT: A 3-Year Follow-up
Shemesh, J., Apter, S., Stroh, C. I., et al. (2000) · Radiology · doi:10.1148/radiology.217.2.r00nv25461 · Cited by 32 · see citing works
Brown, B. G., & Zhao, X.-Q. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.12.014 · Cited by 28 · see citing works
Self-citationDiagnostic and prognostic value of coronary artery calcium screening
Bellasi, A., & Raggi, P. (2005) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000172704.83016.26 · Cited by 25 · see citing works
Jellinger, P. S., Dickey, R. A., & Ganda, P. (2000) · Cited by 23 · see citing works
Chen, F., Maccubbin, D., Yan, L., Sirah, W., Chen, E., Sisk, C. M., Davidson, M. H., Blomqvist, P., & McKenney, J. M. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.12.103 · Cited by 18 · see citing works
Statin therapy in primary and secondary cardiovascular disease prevention
Paparodis, R. D., Bantouna, D., Livadas, S., & Angelopoulos, N. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01265-9 · Cited by 17 · see citing works
“The combined intake of lovastatin with a bile acid sequestrant for 2.5 years slowed the progression and increased the regression of coronary atherosclerotic lesions compared to niacin in the FATS study [38].”
InfluentialKush, D. A., Hu, D., Ye, P., Kim, H.-S., Chen, E., Sirah, W., Sisk, C. M., Paolini, J. F., & Maccubbin, D. (2009) · Cardiology · doi:10.1159/000228585 · Cited by 17 · see citing works
Rhodes, T., Norquist, J. M., Sisk, C. M., McQuarrie, K., Trovato, A., Liao, J., Miller, T., Maccubbin, D., & Watson, D. J. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12213 · Cited by 13 · see citing works
Biodegradable polymeric stents for vascular application in a porcine carotid artery model
Kischkel, S., Grabow, N., Püschel, A., et al. (2015) · Gefässchirurgie · doi:10.1007/s00772-015-0011-z · Cited by 11 · see citing works
“In addition to their main action, low-density lipoprotein (LDL) cholesterol reduction, statins also stabilize plaque [11] and demonstrably reduce restenosis rates [12].”
BackgroundBlack, D. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02325-6 · Cited by 10 · see citing works
Michailov, G. V., Davies, G., & Krobot, K. J. (2011) · The European Journal of Health Economics · doi:10.1007/s10198-011-0309-z · Cited by 9 · see citing works
The high-fat high-fructose hamster as an animal model for niacin’s biological activities in humans
Connolly, B. A., O’Connell, D. P., Lamon‐Fava, S., LeBlanc, D. F., Kuang, Y., Schaefer, E. J., Coppage, A. L., Benedict, C. R., Kiritsy, C. P., & Bachovchin, W. W. (2013) · Metabolism · doi:10.1016/j.metabol.2013.08.001 · Cited by 9 · see citing works
Venkatesh, P. K., Caskey, D., & Reddy, P. C. (2008) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31815d4419 · Cited by 8 · see citing works
Beyond the cholesterol profile: Monitoring therapeutic effectiveness of statin therapy
Schwartz, R. G. (2001) · Journal of Nuclear Cardiology · doi:10.1067/mnc.2001.116847 · Cited by 6 · see citing works
McKenney, J. M., Gandhi, S. K., Fox, K. M., & Ohsfeldt, R. L. (2009) · Journal of clinical lipidology · doi:10.1016/j.jacl.2009.10.004 · Cited by 4 · see citing works
Ohsfeldt, R. L., Gandhi, S. K., & Fox, K. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902905658 · Cited by 4 · see citing works
Tabas, I. A., & Kovanen, P. T. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200010000-00001 · Cited by 4 · see citing works
Electron beam tomography as an endpoint for clinical trials of antiatherosclerotic therapy
Raggi, P. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0060-x · Cited by 4 · see citing works
Best practice — ongoing polemics
Paoletti, R., & Bellosta, S. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00100-8 · Cited by 3 · see citing works
Sliskovic, D. R. (2013) · Drug Discovery · doi:10.1002/9781118354483.ch5 · Cited by 4 · see citing works
(2011) · doi:10.1002/9781118158678.ch12 · Cited by 2 · see citing works
Efficacy of Two Lipid-Lowering Treatments on Quantitative Coronary Angiographic Endpoints
Mack, W., Xiang, M., Shircore, A., Selzer, R., Hodis, H., & Azen, S. (2000) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007816300468 · Cited by 2 · see citing works
“Examination of treatment responses by lesion subsets therefore has important implications for trial design, endpoint definition, and patient selection [26].”
BackgroundNúñez-Cortés, J. M., Álvarez-Sala, J. L., García-Andrade, C. R., Civeira, M. F., Novés, G. Á., & Rodríguez, Y. A. (2012) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2012.04.002 · Cited by 1 · see citing works
Pleiotropic effects of HMG-CoA reductase inhibitors on cells of the vascular wall
Node, K., & Liao, J. K. (2002) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8135-7_5 · Cited by 1 · see citing works
Lipids, Atherogenic Dyslipidemia, and Therapy
Levine, T. B., & Levine, A. B. (2012) · Wiley eBooks · doi:10.1002/9781118480045.ch13 · Cited by 1 · see citing works
A study of natural killer cells in renal failure and in patients at cardiovascular risk
Wan, R. K. (2012) · Enlighten: Theses (The University of Glasgow) · Cited by 1 · see citing works
Modelos animales de aterosclerosis. Contribución al estudio del mecanismo de acción de las estatinas
Sánchez, R. M. G. (2002) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(02)78869-4 · Cited by 1 · see citing works
Future Strategies in the Management of Dyslipidemia
Birjmohun, R. S., Stroes, E. S. G., & Kastelein, J. J. P. (2005) · Future Cardiology · doi:10.1517/14796678.1.2.127 · Cited by 1 · see citing works
“In this respect, two recent smaller trials evaluating niacin combined with either a bile acid sequestrant or a statin reported large HDL increases ranging from 25 to 41% with a profound reduction of cardiovascular event rates ranging from 60–72% [10,11].”
BackgroundSupporting smoking cessation in the medical specialist practice.
Schippers, G. M. (2004) · PubMed · Cited by 1 · see citing works
Anticoagulant Effects of Statins
Wang, J., Mehta, J. L., Fink, L. M., et al. (2004) · Elsevier eBooks · doi:10.1016/b978-0-7216-0380-3.50017-x · Cited by 1 · see citing works
Bokemeyer, J. (2009) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-10913
Accurate Lumen Identification, Detection, and Quantification in MR Plaque Volumes
Suri, J. S., Pappu, V., Salvado, O., Fei, B., Laxminarayan, S., Zhang, S., Lewin, J. S., Duerk, J. L., & Wilson, D. L. (2007) · Springer eBooks · doi:10.1007/0-306-48606-7_9
Biodegradierbare Polymerstents für die vaskuläre Applikation im Karotis-Modell beim Schwein
Kischkel, S., Grabow, N., Püschel, A., et al. (2014) · Gefässchirurgie · doi:10.1007/s00772-014-1311-4
Einfache Therapie fördert die Compliance
Mühlbauer, B. (2012) · CardioVasc · doi:10.1007/s15027-012-0333-7
“Als Hinweis auf eine plaquestabilisierende Wirkung zeigte sich in der FATS-Studie eine Reduktion der Inzidenz koronarer Ereignisse durch Statine um 70%, obwohl die Reduktion morphologisch koronarer Läsionen weniger als 1% betrug [10].”
BackgroundDiabetes and Atherosclerosis: The Diabetes Atherosclerosis Intervention Study (Dais)
Steiner, G. (1996) · Medical science symposia series · doi:10.1007/978-94-009-0311-1_47
Effects of Statins on C-Reactive Protein: Are All Statins Similar?
Devaraj, S., & Jialal, I. (2004) · Elsevier eBooks · doi:10.1016/b978-0-7216-0380-3.50014-4
Atkinson, M. J. (2015) · doi:10.18666/test-2015-v2-i1-7110
Keystones in hypercholesterolemia treatment epidemiology
Martinez, T. L. D. R. (2020) · International Journal of Family & Community Medicine · doi:10.15406/ijfcm.2020.04.00179
“• FATS- Study on the Treatment of Familial Atherosclerosis [17,21] 146 men underwent dietary and drug treatment for 2 and a half years, divided into groups that received colestipol more niacin or more lovastatin or more placebo.”
MethodCoronary Artery Imaging Using EBT
Raggi, P. (2002) · Springer eBooks · doi:10.1007/978-3-642-56225-9_33
- Authors
- BROWN, B. G., HILLGER, L., ZHAO, X., POULIN, D., & ALBERS, J. J.
- Affiliations
- University of Washington (US)
- Corresponding author
- BROWN, B. GREG
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 1994-01
- Volume
- 748
- Issue
- 1
- Pages
- 407-417
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2170791595
- Cited by
- 61
- References
- 15
- Citations by year
- 2024: 1 · 2020: 1 · 2017: 1 · 2015: 2 · 2014: 1 · 2013: 4 · 2012: 7
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of the New York Academy of Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hl019451-14)
- U.S. Public Health Service (P01 H1 30086)
- National Heart, Lung, and Blood Institute (R01 HL 19451)
- National Center for Research Resources (RR 37)
- Topics
- Health Sciences › Medicine › Surgery › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- coronary artery stenosis, lesion severity, coronary artery disease progression, plaque regression, plaque progression, coronary angiography
- MeSH terms
- Adult, Colestipol, Coronary Disease, Humans, Lovastatin, Male, Middle Aged, Niacin, Diet, Fat-Restricted
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
